An H10N8 influenza virus vaccine strain and mouse challenge model based on the human isolate A/Jiangxi-Donghu/346/13

Wohlbold, Teddy John; Hirsh, Ariana; Krammer, Florian

doi:10.1016/j.vaccine.2015.01.026

Cited by 15 publications

(12 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Protection against heterologous H10 challenge was demonstrated using vaccination with either mono- or quadri-subtype VLPs. Other strategies to protect from H10 influenza include HA stalk- and NA-specific monoclonal antibodies, as well as a 6:2 reassortant virus expressing the surface glycoproteins of A/Jiangxi-Donghu/346/13 (H10N8) on an A/Puerto Rico/8/34 backbone [44, 45]. Although in the current study we did not challenge vaccinated animals with multiple influenza viruses, we previously showed that VLPs displaying three HA subtypes are capable of protecting against multiple homologous virus challenges [20, 21, 42].…”

Section: Discussionmentioning

confidence: 99%

Mono- and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model

Pushko

Sun

Tretyakova

et al. 2016

Vaccine

View full text Add to dashboard Cite

Avian-origin influenza represents a global public health concern. In 2013, the H10N8 virus caused documented human infections for the first time. Currently, there is no approved vaccine against H10 influenza. Recombinant virus-like particles (VLPs) represent a promising vaccine approach. In this study, we evaluated H10 VLPs containing hemagglutinin from H10N8 virus as an experimental vaccine in a ferret challenge model. In addition, we evaluated quadri-subtype VLPs co-localizing H5, H7, H9 and H10 subtypes. Both vaccines elicited serum antibody that reacted with the homologous H10 derived from H10N8 virus and cross-reacted with the heterologous H10N1 virus. Quadri-subtype vaccine also elicited serum antibody to the homologous H5, H7, and H9 antigens and cross-reacted with multiple clades of H5N1 virus. After heterologous challenge with the H10N1 virus, all vaccinated ferrets showed significantly reduced titers of replicating virus in the respiratory tract indicating protective effect of vaccination with either H10 VLPs or with quadri-subtype VLPs.

show abstract

Section: Discussionmentioning

confidence: 99%

Mono- and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model

Pushko

Sun

Tretyakova

et al. 2016

Vaccine

View full text Add to dashboard Cite

show abstract

“…At 2 h after treatment, the mice were anesthetized using a ketamine-xylazine mixture and infected with 5ϫ the 50% lethal dose (LD 50 ) of JD13 (H10N8) virus diluted in PBS (pH 7.4). The LD 50 of this virus in BALB/c mice has been previously determined and characterized in detail (21). In a therapeutic setting, mice received a 5-mg/kg dose of each antibody intraperitoneally 48 h after infection.…”

Section: Fig 1 Anti-h10 and Anti-n8 Antibodies Display Heterologous Cmentioning

confidence: 99%

“…The influenza viruses A/mallard/IA/10BM01929/10 (H10N7), A/Northern shoveler/Alaska/7MP1708/07 (H3N8), and JD13 (A/Puerto Rico/8/1934 [PR8, H1N1] internal genes and hemagglutinin [HA] and neuraminidase [NA] from A/Jiangxi-Donghu/346/13 [H10N8]) (21) were grown in 8-to 10-day-old embryonated chicken eggs, and titers were determined on MDCK cells in the presence of TPCK (tolylsulfonyl phenylalanyl chloromethyl ketone)-treated trypsin. The latter JD13 reassortant virus was rescued and characterized as previously described (21).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice

Wohlbold

Chromikova

Tan

et al. 2016

J Virol

Self Cite

View full text Add to dashboard Cite

Between November 2013 and February 2014, China reported three human cases of H10N8 influenza virus infection in the Jiangxi province, two of which were fatal. Using hybridoma technology, we isolated a panel of H10-and N8-directed monoclonal antibodies (MAbs) and further characterized the binding reactivity of these antibodies (via enzyme-linked immunosorbent assay) to a range of purified virus and recombinant protein substrates. The H10-directed MAbs displayed functional hemagglutination inhibition (HI) and neutralization activity, and the N8-directed antibodies displayed functional neuraminidase inhibition (NI) activity against H10N8. Surprisingly, the HI-reactive H10 antibodies, as well as a previously generated, group 2 hemagglutinin (HA) stalk-reactive antibody, demonstrated NI activity against H10N8 and an H10N7 strain; this phenomenon was absent when virus was treated with detergent, suggesting the anti-HA antibodies inhibited neuraminidase enzymatic activity through steric hindrance. We tested the prophylactic efficacy of one representative H10-reactive, N8-reactive, and group 2 HA stalk-reactive antibody in vivo using a BALB/c challenge model. All three antibodies were protective at a high dose (5 mg/kg). At a low dose (0.5 mg/kg), only the anti-N8 antibody prevented weight loss. Together, these data suggest that antibody targets other than the globular head domain of the HA may be efficacious in preventing influenza virus-induced morbidity and mortality. IMPORTANCEAvian H10N8 and H10N7 viruses have recently crossed the species barrier, causing morbidity and mortality in humans and other mammals. Although these reports are likely isolated incidents, it is possible that more cases may emerge in future winter seasons, similar to H7N9. Furthermore, regular transmission of avian influenza viruses to humans increases the risk of adaptive mutations and reassortment events, which may result in a novel virus with pandemic potential. Currently, no specific therapeutics or vaccines are available against the H10N8 influenza virus subtype. We generated a panel of H10-and N8-reactive MAbs. Although these antibodies may practically be developed into therapeutic agents, characterizing the protective potential of MAbs that have targets other than the HA globular head domain will provide insight into novel antibody-mediated mechanisms of protection and help to better understand correlates of protection for influenza A virus infection. R ecently, avian influenza A viruses of the H10 subtype have been reported to infect seals and humans and have generated concern over their pandemic potential. Three human cases of H10N8 virus have been reported in China so far, two of which were fatal (1-3). Furthermore, an avian H10N7 strain was found to be the etiological agent responsible for the massive die-off harbor seals in the Baltic Sea, an epidemic that killed more than 10% of the local seal population (4-6). The receptor binding profile of H10 viruses is currently debated (7-12), but the subtype has been proven to cause ...

show abstract

“…an H3N2 variant that spilled over into humans attending agricultural shows in the early 2010s, H3N2v (Jhung et al, 2013). In addition, zoonotic infections with other viruses from poultry or wild birds have occurred, including for example H7N7 (Fouchier et al, 2004), H10N8 (Wohlbold et al, 2015), H6N1 (Wei et al, 2013), H9N2 (Butt et al, 2005), and H5N6 (Yang et al, 2015); for more examples and a fuller discussion see (Short et al, 2015). The severity of zoonotic influenza A infections ranges from clinically inapparent (Gomaa et al, 2015; To et al, 2016) to fatal (de Jong et al, 2006; Gao et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Viral factors in influenza pandemic risk assessment

Lipsitch

Barclay

Raman

et al. 2016

eLife

View full text Add to dashboard Cite

The threat of an influenza A virus pandemic stems from continual virus spillovers from reservoir species, a tiny fraction of which spark sustained transmission in humans. To date, no pandemic emergence of a new influenza strain has been preceded by detection of a closely related precursor in an animal or human. Nonetheless, influenza surveillance efforts are expanding, prompting a need for tools to assess the pandemic risk posed by a detected virus. The goal would be to use genetic sequence and/or biological assays of viral traits to identify those non-human influenza viruses with the greatest risk of evolving into pandemic threats, and/or to understand drivers of such evolution, to prioritize pandemic prevention or response measures. We describe such efforts, identify progress and ongoing challenges, and discuss three specific traits of influenza viruses (hemagglutinin receptor binding specificity, hemagglutinin pH of activation, and polymerase complex efficiency) that contribute to pandemic risk.DOI: http://dx.doi.org/10.7554/eLife.18491.001

show abstract

An H10N8 influenza virus vaccine strain and mouse challenge model based on the human isolate A/Jiangxi-Donghu/346/13

Cited by 15 publications

References 20 publications

Mono- and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model

Mono- and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model

Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice

Viral factors in influenza pandemic risk assessment

Contact Info

Product

Resources

About